Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glenmark’s Melogliptin To Enter Phase-III Trials
Glenmark’s Melogliptin has recently completed 12 weeks phase-IIb clinical trial in 494 patients with type 2 diabetes mellitus, and is now ready to initiate phase III trials. In
Glenmark’s Melogliptin has recently completed 12 weeks phase-IIb clinical trial in 494 patients with type 2 diabetes mellitus, and is now ready to initiate phase III trials. In
Perrigo’s partner Synthon has filed an ANDA for Levocetirizine solution 2.5mg/5ml, a generic version of Xyzal solution 2.5mg/5ml. Xyzal solution 2.5mg/5ml is meant for the treatment of allergies
Conatus Pharmaceuticals (Conatus) has initiated the second phase-II clinical trial with a drug candidate, for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The
ImmunoCellular (IMUC) has signed an agreement with Formatech for the manufacture of IMUC’s cancer stem cell vaccine, ICT-121, for an upcoming clinical trial. ICT-121 is a product candidate
Watson has announced that its subsidiary, Watson Laboratories, has received FDA approval for its Abbreviated New Drug Application (ANDA). The approval is meant for its levonorgestrel tablets, 0.75
Actavis has launched Finasteride in France, just one day before the patent expired. The distribution of the product has already been initiated. Finasteride Actavis was launched by the
OncoGenex has signed an agreement with FDA via the special protocol assessment process (SPA), on an amendment to the design of a phase-III registration trial of OGX-011. It
Spherix has announced positive preliminary results from phase-II clinical trial of Naturlose (D-tagatose), in the treatment and management of Type 2 diabetes. The phase-II trial was single-blind, prospective,
DiaGenic has signed an agreement with Merz Pharmaceuticals to gain access to biomarkers for Mild Cognitive Impairment (MCI), increasingly considered a transitional stage to Alzheimer’s disease. The biomarkers
Gentiva Health Services, a provider of comprehensive home health services, has acquired Mid-State Home Health in Louisiana. Tony Strange, President and CEO, Gentiva, said Combining forces with Mid-State